MARKET

ALGS

ALGS

Aligos Therapeutics, Inc.
NASDAQ

Real-time Quotes | Nasdaq Last Sale

15.54
-1.01
-6.10%
Opening 10:01 07/26 EDT
OPEN
16.39
PREV CLOSE
16.55
HIGH
16.73
LOW
15.36
VOLUME
21.71K
TURNOVER
--
52 WEEK HIGH
37.51
52 WEEK LOW
12.82
MARKET CAP
573.27M
P/E (TTM)
-4.9048
1D
5D
1M
3M
1Y
5Y
Companies Like Aligos Therapeutics (NASDAQ:ALGS) Are In A Position To Invest In Growth
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Simply Wall St. · 07/06 05:37
MFGP, NVCR, SLCA and CTXR among midday movers
Gainers: Alterity Therapeutics Limited (ATHE) +68%.TRxADE HEALTH (MEDS) +57%.Marin Software (MRIN) +45%.Bridgeline Digital (BLIN) +35%.Birks (BGI) +25%.Pulse Biosciences (PLSE) +25%.SGOCO Group (SGOC) +22%.Grid Dynamics Holdings (GDYN) +19%.scPharmaceutica...
Seekingalpha · 07/01 17:06
12 Health Care Stocks Moving In Thursday's Intraday Session
Gainers
Benzinga · 07/01 16:43
Aligos Therapeutics Offering of 4.4 Million Shares Prices at $19/Shr
marketwatch.com · 07/01 13:08
Aligos Therapeutics Raises $84M Via Equity At 7% Discount
Benzinga · 07/01 11:25
Aligos Therapeutics secures $83.6M capital via equity raise
Aligos Therapeutics (ALGS) has priced its public offering of 4.4M common shares at $19.00/share for expected gross proceeds of ~$83.6M.Underwriters' over-allotment is an additional 660K shares.Closing date is July 6.
Seekingalpha · 07/01 03:45
BRIEF-Aligos Therapeutics Announces Pricing Of $83.6 Million Public Offering Of Common Stock
reuters.com · 07/01 02:10
Technology and Healthcare names dominate midday movers
Gainers: BSQUARE Corporation (BSQR) +99%.Cerevel Therapeutics Holdings (CERE) +94%.Marin Software Incorporated (MRIN) +73%.Exela Technologies (XELA) +43%.Weidai (WEI) +39%.Infobird (IFBD) +36%.Powerbridge Technologies (PBTS) +31%.Auddia (AUUD) +23%.Amesite...
Seekingalpha · 06/29 16:34
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ALGS. Analyze the recent business situations of Aligos Therapeutics, Inc. through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ALGS stock price target is 39.00 with a high estimate of 47.00 and a low estimate of 28.00.
EPS
Institutional Holdings
Institutions: 51
Institutional Holdings: 29.19M
% Owned: 79.13%
Shares Outstanding: 36.89M
TypeInstitutionsShares
Increased
19
590.80K
New
7
128.04K
Decreased
9
164.15K
Sold Out
8
793.27K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.79%
Pharmaceuticals & Medical Research
-0.53%
Key Executives
Non-Executive Chairman/Independent Director
Jack Nielsen
President/Director
Leonid Beigelman
Chief Executive Officer/Director
Lawrence Blatt
Chief Financial Officer/Executive Vice President
Lesley Calhoun
Executive Vice President/Chief Scientific Officer
Julian Symons
Executive Vice President/General Counsel
Lucinda Quan
Independent Director
K. Peter Hirth
Independent Director
Peter Moldt
Independent Director
Carole Nuechterlein
Independent Director
James Scopa
Independent Director
Thomas Woiwode
No Data
  • All
  • Financials
  • Insiders
More
About ALGS
Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapeutics to address unmet medical needs in viral and liver diseases. It uses its oligonucleotide and small molecule platforms to develop pharmacologically optimized drug candidates for use in combination regimens. It is initially focused on developing functional cure for Chronic Hepatitis B (CHB); cirrhosis, end-stage liver disease (ESLD) and hepatocellular carcinoma (HCC). It developing a portfolio of differentiated drug candidates for CHB, including an S-antigen Transport-inhibiting Oligonucleotide Polymers (STOPS) molecule, a small molecule Capsid Assembly Modulator (CAM), and oligonucleotides, such as ASO and Small interfering RNA (siRNA), each of which is designed against targets in the Hepatitis B Virus (HBV) life cycle. The Company's pipeline includes ALG-010133, ALG-000184, ALG-020572, ALG-125097 and ALG-055009.

Webull offers kinds of Aligos Therapeutics Inc stock information, including NASDAQ:ALGS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ALGS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ALGS stock methods without spending real money on the virtual paper trading platform.